E
Engimmune Therapeutics
Platform and product development company engineering next-generation T cell receptor therapies
About Engimmune Therapeutics
Engimmune Therapeutics is a leading biotechnology startup that specializes in the development of soluble T-cell receptor drugs (TCRs) for the treatment of solid tumor cancers. In simpler terms, they create drugs that can help the body's immune system fight cancer more effectively. Their primary market is the healthcare sector, specifically oncology, where they cater to patients suffering from solid tumor cancers.
Read full description
The company's unique selling proposition lies in its proprietary platform technologies. These technologies allow Engimmune to quickly identify and engineer TCRs that have high target affinity, enhanced stability, and superior safety. This means they can create drugs that are highly effective, stable, and safe for patients.
Moreover, Engimmune utilizes artificial intelligence (AI) to guide their protein engineering platforms. This AI-guided approach helps them overcome challenges associated with TCR development, enabling them to unlock thousands of new targets for cancer treatment. This not only increases the potential for creating transformative treatments for solid cancers but also for immune-mediated diseases.
Engimmune operates on a business model that involves the research, development, and commercialization of their TCR drugs. They generate revenue through the sale of these drugs to healthcare providers and patients. Additionally, they may also earn income through partnerships with other pharmaceutical companies for the development and distribution of their drugs.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Allschwil, Switzerland
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 56.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, Digital Pharma, proteomics, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2022 | $14M | $57M | Novo Seeds · Pureos Bioventures · Novo Holdings | ↗ |
| SPINOUT✓Other financing | Apr 2022 | $0 | — | ETH Zurich | — |
Growth signals
Latest recorded traffic for Engimmune Therapeutics is 130 monthly website visits, up 62.5% over the last three months. Engimmune Therapeutics's team declined 52% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
BaseLaunch
Novo Seeds
Pureos Bioventures
Novo Holdings
Other known investors1 additional known investor
ETH Zurich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Engimmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Engimmune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.